SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (195)4/30/2004 10:16:06 AM
From: rkrw  Read Replies (2) | Respond to of 255
 
Bummer. I still think ardm may have a better mousetrap than nktr. But ardm can't seem to catch a break.



To: tuck who wrote (195)4/30/2004 11:21:31 AM
From: keokalani'nui  Read Replies (1) | Respond to of 255
 
>>during the nighttime, plasma glucose levels were lower in the AERx iDMS group compared to the subcutaneous group<<

It was probably this finding, not the post-prandial elevation, that killed the trial.

Wonder why they couldn't continue the trial for the T2 diabetics.

Antibodies also.

Just bought a couple ardm tickets at $1.2, some alth too, but no gnta.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News